首页> 外文期刊>Expert opinion on biological therapy >Role of abciximab in the treatment of coronary artery disease.
【24h】

Role of abciximab in the treatment of coronary artery disease.

机译:阿昔单抗在冠状动脉疾病治疗中的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Glycoprotein IIb/IIIa complex is a crucial membrane receptor for platelet aggregation, binding platelets to fibrinogen and establishing interplatelet bridges. This receptor is the common end point of the multiple activation pathways of a platelet. Antiplatelet agents, such as aspirin or thienopyridines, including ticlopidine and clopidogrel, inhibit one or more but not all, of these pathways. Inhibitors of the receptor are powerful platelet antiaggregants and include two groups of agents: non-competitive receptor blockers, such as abciximab, and competitive antagonists, such as tirofiban and eptifibatide. Abciximab is a monoclonal antibody that binds to the glycoprotein IIb/IIIa complex, thus blocking the interaction with fibrinogen. It is used for treatment of coronary artery disease, being well-studied in the setting of acute coronary syndromes and percutaneous coronary intervention, in which a rapid and effective antiaggregation is clinically important.
机译:糖蛋白IIb / IIIa复合物是血小板聚集,将血小板与纤维蛋白原结合并建立血小板间桥的关键膜受体。该受体是血小板的多种激活途径的共同终点。抗血小板药,例如阿司匹林或噻吩并吡啶类,包括噻氯匹定和氯吡格雷,可抑制这些途径中的一种或多种,​​但不是全部。该受体的抑制剂是强大的血小板抗凝剂,包括两类药物:非竞争性受体阻滞剂(例如abciximab)和竞争性拮抗剂(例如替罗非班和依替非巴肽)。 Abciximab是一种单克隆抗体,可与糖蛋白IIb / IIIa复合物结合,从而阻断与纤维蛋白原的相互作用。它被用于治疗冠状动脉疾病,在急性冠脉综合征和经皮冠状动脉介入治疗中得到了充分的研究,其中快速有效的抗凝集在临床上很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号